Tango Therapeutics : TNGX

TNGX

Stock Data

$20.98

$0.64 (2.96%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Tango Therapeutics Inc is a pioneering biotech firm based in Boston, Massachusetts, focused on crafting innovative cancer treatments. With a robust pipeline, including its flagship TNG908 designed to inhibit specific proteins for treating certain cancer types, Tango is at the forefront of developing therapies for challenging conditions like BRCA1 or BRCA2-mutant cancers. Their collaboration with Gilead Sciences underscores their commitment to advancing cancer care through strategic partnerships, aiming to bring new hope to patients worldwide.

All Tango Therapeutics Articles

1 Article

Joel South | Mar 9, 2026 at 11:15 AM EDT

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional…

Tango Therapeutics : TNGX

TNGX

$20.98

All Tango Therapeutics Articles

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Tango Therapeutics : TNGX

TNGX

$20.98

All Tango Therapeutics Articles

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

Featured Reads

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened